Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Morning or evening? timing your RA pill could boost relief

NCT ID NCT07674134

Disease control Sponsor: Centre Hospitalier Princesse Grace Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study tests whether taking a once-daily JAK inhibitor for rheumatoid arthritis in the evening works better than taking it in the morning. About 90 adults with RA who qualify for this medication will be randomly assigned to morning or evening dosing. Researchers will compare how many people achieve a good response (based on EULAR criteria) and track side effects and disease activity over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
JAK inhibitor (taken once daily)
What this could lead to
If timing matters, this could help people with rheumatoid arthritis get better symptom control by simply adjusting when they take their medication.
What could go wrong
This is a small study (90 people) looking at timing, not a new drug. The benefit may be small or not apply to everyone, and side effects could still occur regardless of timing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2024

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with rheumatoid arthritis, treated at the Princess Grace Hospital Centre. It will take place in the Rheumatology department.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient aged over 18 years * Patient with Rheumatoid Arthritis according to the 2010 ACR/EULAR criteria * Patient meeting the criteria for initiation of a JAK inhibitor according to the marketing authorization and international recommendations * Patient capable of providing informed, written, dated, and signed consent before the start of any trial-related procedure. Exclusion Criteria: * No contraindication to a bDMARD * Not stable dose of corticosteroids in the 4 weeks preceding enrollment * Not stable dose of maintenance therapy (methotrexate, leflunomide, hydroxychloroquine, cyclosporine, gold salts) in the 4 weeks preceding enrollment * Prior treatment with a JAK inhibitor * Patient unable to be followed-up in the study during 6 months * Minors or adults under guardianship or curatorship, or deprived of their liberty * Pregnant or breastfeeding patient * Patient refusing to use an effective method of contraception for the duration of the study * Person not affiliated with a social security scheme.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rheumatoid arthritis (RA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rheumatoid arthritis (RA

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier Princesse Grace

    RECRUITING

    Monaco, 98000, Monaco

More trials for these conditions

Other studies related to the condition(s) this trial covers.